HAYWARD, Calif. (AP) — Impax Laboratories Inc. said Wednesday it acquired the rights to two potential generic drugs from Watson Pharmaceuticals Inc. Impax bought the abbreviated new drug applications for a version of Dronabinol and a version of Dostinex. Dronabinol is a generic equivalent to Marinol, an anti-nausea drug that includes the active ingredient in marijuana. Dostinex, or cabergoline, treats overproduction of the hormone prolactin. Abbreviated new drug applications are requests for Food and Drug Administration approval for a generic version of a drug that is already on the market. Impax said it acquired the drugs from Watson and Cobalt Laboratories in connection with Watson’s purchase of Arrow Group. Cobalt is a unit of Arrow Group.
Related Articles Read More >
Confidently navigate the transition from bench to batch
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
